Last reviewed · How we verify
Placebo(for Rosuvastatin 20mg)
Placebo(for Rosuvastatin 20mg) is a Small molecule drug developed by IlDong Pharmaceutical Co Ltd. It is currently in Phase 3 development for Control arm in phase 3 trial for Rosuvastatin 20mg (hyperlipidemia/cardiovascular risk reduction).
Placebo is an inert substance with no active pharmacological mechanism.
Placebo is an inert substance with no active pharmacological mechanism. Used for Control arm in phase 3 trial for Rosuvastatin 20mg (hyperlipidemia/cardiovascular risk reduction).
At a glance
| Generic name | Placebo(for Rosuvastatin 20mg) |
|---|---|
| Sponsor | IlDong Pharmaceutical Co Ltd |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Placebo is used as a control in clinical trials to establish the true efficacy of an active drug by comparison. It contains no active ingredient and produces no direct therapeutic effect, allowing researchers to measure the drug's actual benefit independent of psychological or natural disease progression effects.
Approved indications
- Control arm in phase 3 trial for Rosuvastatin 20mg (hyperlipidemia/cardiovascular risk reduction)
Common side effects
Key clinical trials
- Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine (PHASE4)
- PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis (PHASE3)
- Statins to Prevent Cancer Associated Blood Clots (PHASE4)
- Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients (PHASE4)
- High-Dose Rosuvastatin Preloading for Enhanced Outcomes in STEMI Patients Undergoing Primary PCI (PHASE2)
- Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD (PHASE4)
- STAT-STatin and Aspirin in Trauma (PHASE2)
- Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo(for Rosuvastatin 20mg) CI brief — competitive landscape report
- Placebo(for Rosuvastatin 20mg) updates RSS · CI watch RSS
- IlDong Pharmaceutical Co Ltd portfolio CI
Frequently asked questions about Placebo(for Rosuvastatin 20mg)
What is Placebo(for Rosuvastatin 20mg)?
How does Placebo(for Rosuvastatin 20mg) work?
What is Placebo(for Rosuvastatin 20mg) used for?
Who makes Placebo(for Rosuvastatin 20mg)?
What development phase is Placebo(for Rosuvastatin 20mg) in?
Related
- Manufacturer: IlDong Pharmaceutical Co Ltd — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Control arm in phase 3 trial for Rosuvastatin 20mg (hyperlipidemia/cardiovascular risk reduction)
- Compare: Placebo(for Rosuvastatin 20mg) vs similar drugs
- Pricing: Placebo(for Rosuvastatin 20mg) cost, discount & access